THTX

Theratechnologies Inc. [THTX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

THTX Stock Summary

Top 10 Correlated ETFs

THTX

Top 10 Correlated Stocks

THTX

In the News

THTX Financial details

Company Rating
-
Market Cap
65.29M
Income
-17.95M
Revenue
77.94M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
103
Optionable
No
Shortable
Yes
Earnings
10 Jul 2024
P/E
-1.81
Forward P/E
-
PEG
0.26
P/S
0.66
P/B
-1.27
P/C
-
P/FCF
-5.2
Quick Ratio
0.33
Current Ratio
0.42
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.62
EPS next Y
-
EPS next Q
-
EPS this Y
-54.04%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
6.96%
Revenue last 5Y
5.28%
Revenue Q/Q
-31.41%
EPS Q/Q
20.63%
-
-
-
-
SMA20
5.16%
SMA50
-
SMA100
33.61%
Inst Own
-
Inst Trans
-
ROA
-51%
ROE
84%
ROC
0.46%
Gross Margin
74%
Oper. Margin
-24%
Profit Margin
-37%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.88-4.32
52W High
-
52W Low
-
RSI
39.97
Rel Volume
1.29
Avg Volume
59.13K
Volume
76.04K
Perf Week
-5%
Perf Month
-12.14%
Perf Quarter
22.58%
Perf Half Y
26.67%
-
-
-
-
Beta
1.725
-
-
Volatility
0.05%, 0.13%
Prev Close
-1.94%
Price
1.52
Change
-4.4%

Something similar

Top by Market Cap
ABEA.DE
M&M.NS
VTI
LLY
1YD.DE
Top Correlated ETFs
ARVR
GAMR
NERD
ESPO
BNGE
Top Correlated Stocks
TH.TO
ABBB
TSE
SMCI
SRL
Similar Market Cap
SINO
C101.DE
BZUN
LACR.PA
BTAI

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 59.13K
  • Market Capitalization 65.29M
  • Employee 103
  • CEO Mr. Paul Lévesque
  • Headquarters Montreal,QC,CA
  • IPO Date 2009-02-13
  • Website https://www.theratech.com

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.